ATE214100T1 - Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem - Google Patents

Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem

Info

Publication number
ATE214100T1
ATE214100T1 AT95902725T AT95902725T ATE214100T1 AT E214100 T1 ATE214100 T1 AT E214100T1 AT 95902725 T AT95902725 T AT 95902725T AT 95902725 T AT95902725 T AT 95902725T AT E214100 T1 ATE214100 T1 AT E214100T1
Authority
AT
Austria
Prior art keywords
bovine adenovirus
production
expression vector
recombinant proteins
vector system
Prior art date
Application number
AT95902725T
Other languages
English (en)
Inventor
Suresh K Mittal
Frank L Graham
Ludvik Prevec
Lorne A Babiuk
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Application granted granted Critical
Publication of ATE214100T1 publication Critical patent/ATE214100T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT95902725T 1993-12-09 1994-12-09 Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem ATE214100T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/164,292 US5820868A (en) 1993-12-09 1993-12-09 Recombinant protein production in bovine adenovirus expression vector system
PCT/CA1994/000678 WO1995016048A2 (en) 1993-12-09 1994-12-09 Recombinant protein production in bovine adenovirus expression vector system

Publications (1)

Publication Number Publication Date
ATE214100T1 true ATE214100T1 (de) 2002-03-15

Family

ID=22593842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902725T ATE214100T1 (de) 1993-12-09 1994-12-09 Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem

Country Status (6)

Country Link
US (5) US5820868A (de)
EP (1) EP0736100B1 (de)
AT (1) ATE214100T1 (de)
AU (1) AU1189195A (de)
DE (1) DE69430071T2 (de)
WO (1) WO1995016048A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
FR2748753B1 (fr) * 1996-05-20 1998-08-14 Transgene Sa Nouveaux vecteurs adenoviraux pour la therapie genique
EP0979101B1 (de) * 1996-07-03 2010-10-27 Merial, Inc. Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6420629B1 (en) * 1996-09-09 2002-07-16 B.C. Research Inc. Process of increasing plant growth and yield and modifying cellulose production in plants
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
CA2294649C (en) * 1997-06-23 2007-09-25 University Of Saskatchewan Bovine adenovirus type 3 genome
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
US6458586B1 (en) * 1998-11-02 2002-10-01 University Of Saskatchewan Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
JP2002541815A (ja) * 1999-04-09 2002-12-10 シェーリング−プラウ・リミテッド ウシアデノウイルス１型から誘導された組換えアデノウイルスおよび変異アデノウイルス
US6451319B1 (en) * 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
AU6280600A (en) * 1999-08-06 2001-03-05 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Non-human adenoviral vector for gene transfer, its use and the production thereof
JP4799789B2 (ja) * 1999-08-25 2011-10-26 メルク・シャープ・エンド・ドーム・コーポレイション ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
AU6368901A (en) * 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
WO2003025161A1 (en) 2001-09-18 2003-03-27 Clontech Laboratories, Inc. Site-specific recombinase based method for producing adenoviral vectors
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン，インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
AU2003255967A1 (en) * 2002-07-19 2004-02-09 University Of Saskatchewan Pav regions for encapsidation and e1 transcriptioonal control
WO2004038380A2 (en) * 2002-10-23 2004-05-06 Intronn, Inc. Screening methods for identification of efficient pre-trans-splicing molecules
WO2004108755A2 (en) * 2003-06-10 2004-12-16 University Of Saskatchewan Chimeric adenovirus capsid proteins
WO2004108939A2 (en) * 2003-06-10 2004-12-16 University Of Saskatchewan Bav packaging regions and e1 transcriptional control regions
DK1670925T3 (da) 2003-10-02 2013-07-08 Crucell Holland Bv Pakningsceller til rekombinat adenovirus
WO2005067506A2 (en) * 2004-01-06 2005-07-28 Cedars-Sinai Medical Center Method for monitoring and generating high capacity gutless adenoviral vector
WO2005070948A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
CA2553828A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US7342107B2 (en) * 2004-05-27 2008-03-11 Centocor, Inc. Cynomolgus prostate specific antigen
US20050276758A1 (en) * 2004-06-15 2005-12-15 Marshall Deborah J Method for screening agents against human prostate disease
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
CA2583306A1 (en) * 2004-10-08 2006-08-10 Intronn, Inc. Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
CA2598806A1 (en) * 2005-02-23 2006-08-31 Uab Research Foundation Alkyl-glycoside enhanced vaccination
WO2006113214A2 (en) * 2005-04-11 2006-10-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Vaccine against pandemic strains of influenza viruses
WO2014077782A1 (en) * 2012-11-15 2014-05-22 National University Of Singapore Univariant extrinsic initiator control system for microbes and an in vitro assembly of large recombinant dna molecules from multiple components
KR102543774B1 (ko) 2016-09-20 2023-06-19 베링거잉겔하임베트메디카게엠베하 신규한 프로모터
BR112019005415A2 (pt) 2016-09-20 2019-10-22 Boehringer Ingelheim Vetmedica Gmbh nova vacina contra influenza suína
CA3036291A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New ehv insertion site orf70
BR112019005511A2 (pt) 2016-09-20 2019-10-01 Boehringer Ingelheim Vetmedica Gmbh vetores de adenovírus canino
US10525127B2 (en) * 2018-03-31 2020-01-07 Femtomab P14.7 protein and uses thereof as vaccine adjuvant

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB185573A (en) 1921-07-12 1922-09-14 Richard Saleck Apparatus for measuring off and cutting strings in bundles
US3962424A (en) * 1974-01-31 1976-06-08 Recherche Et Industrie Therapeutiques (R.I.T.) Live brovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
WO1986006409A1 (en) * 1985-05-01 1986-11-06 Genetics Institute, Inc. High level amplification and expression of exogenous dna
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
FR2642797B1 (fr) * 1989-01-10 1991-05-17 Secmair Dispositif d'asservissement de la pression d'appui au sol d'un rouleau equipant une tete de coupe, notamment de fauchage
FR2642767B1 (fr) 1989-01-19 1993-10-01 Transgene Sa Vecteurs d'expression de proteines heterologues dans les cellules eucaryotes, lignees cellulaires obtenues et procede pour leur preparation
DE69027695T2 (de) * 1989-03-24 1997-02-20 Wistar Inst Rekombinanter Cytomegalovirus-Impfstoff
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
FR2657880A1 (fr) * 1990-02-02 1991-08-09 Fondation Nale Transfusion San Production de proteines recombinantes a partir de cellules lymphoblastouides humaines et d'heteromyelomes.
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
WO1996022398A1 (en) 1995-01-17 1996-07-25 Environmental Projects, Inc. Method for purification of saline minerals
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
JP2001520511A (ja) 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション 向標的性アデノウイルス・ベクター
CA2294649C (en) 1997-06-23 2007-09-25 University Of Saskatchewan Bovine adenovirus type 3 genome
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
AU6368901A (en) 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
CA2415347A1 (en) 2000-07-14 2002-01-24 University Of Saskatchewan Adenovirus vectors comprising introns
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030143200A1 (en) * 2001-09-24 2003-07-31 Tikoo Suresh K. Porcine adenovirus E1 region

Also Published As

Publication number Publication date
US20020192185A1 (en) 2002-12-19
US7025967B2 (en) 2006-04-11
WO1995016048A3 (en) 1995-09-28
DE69430071D1 (de) 2002-04-11
AU1189195A (en) 1995-06-27
EP0736100B1 (de) 2002-03-06
DE69430071T2 (de) 2002-11-28
US6086890A (en) 2000-07-11
EP0736100A1 (de) 1996-10-09
WO1995016048A2 (en) 1995-06-15
US5820868A (en) 1998-10-13
US6001591A (en) 1999-12-14
US6379944B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
DE69430071D1 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
US11951120B2 (en) Modification of gene transcription and translation efficiency by 5′UTR sequence variation
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
AU3867789A (en) Recombinant mycobacterial expression vehicles and uses therefor
ATE80180T1 (de) Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels ''protein-engineering''.
BR9205771A (pt) Vetor de vírus recombinantes e processo para a fabricaçao do mesmo
EP0063953A3 (de) Bacillus-Klonierungsvektoren, rekombinante DNA-Moleküle, damit transformierte Bacilluswirte und Verfahren zur Expression fremder DNA-Sequenzen und zur Herstellung von dadurch kodierten Polypeptiden
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
EP0766569A4 (de) Aaw-hülltransporter für den molekularen transfer
ES2177475T1 (es) Genes de corynebacterium glutamicum que codifican proteinas de una ruta metabolica.
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
DK0941318T3 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
IL148021A0 (en) Novel b7-4 molecules and uses therefor
ATE27000T1 (de) Expression von polypeptiden in hefen.
PT728214E (pt) Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
DE69531387D1 (de) Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
NO934431L (no) Boven herpesvirus type 1 delesjonmutanter, vaksiner basert paa disse, samt diagnostiske sett for paavisning av bovin herpesvirus type 1
ATE420182T1 (de) Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren
PT988391E (pt) Vectores adenovirais recombinantes compreendendo uma sequencia de splicing
JP2004500088A5 (de)
Rassoulzadegan et al. Two polyoma virus gene functions involved in the expression of the transformed phenotype in FR 3T3 rat cells I. Localization of a transformation maintenance function in the proximal half of the large T coding region
ES2059431T3 (es) Mutantes de la creatinamidinohidrolasa estables.
EP0688224A4 (de) Ein mutiertes protein und verfahren und materialien zu seiner herstellung und verwendung
ES2120409T3 (es) Nuevos vectores de expresion y metodos para la produccion de proteinas intracelulares.
Tait et al. The production of proteins by bacterial plasmids containing eukaryotic DNA fragments

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties